Sage Therapeutics shares are trading lower after the company stops further development of dalzanemdor in Alzheimer's Disease following disappointing results from the Phase 2 LIGHTWAVE Study.
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics has halted the development of its Alzheimer's drug, dalzanemdor, after unsatisfactory results from the Phase 2 LIGHTWAVE Study, leading to a decline in its stock price.
October 08, 2024 | 10:54 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics has decided to stop the development of dalzanemdor for Alzheimer's Disease due to disappointing Phase 2 study results, resulting in a decline in its stock price.
The halting of a drug's development, especially after a failed Phase 2 trial, is a significant negative event for a biotech company like Sage Therapeutics. This directly impacts investor sentiment and the company's future revenue prospects, leading to a drop in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100